When clinical supply data conflicts, the problem is rarely one bad system. This article shows how clear decision rights turn conflicting signals into action.
- What Your Tier 1 Supplier Map Might Be Missing
- Clinical Trial Supply Chains Need To Prepare For A Less Predictable World
- Root Causes, Part 5: The Structural Changes Clinical Supply Needs
- Rare Disease Trials: Execution Risks No One Warns You About
- Undocumented Changes Break Validated Clinical Systems
- What Happens When The Clinical Forecast Changes?
- The Patient Is In The Room. Who Is Dispensing The IP?
- When Drug Supply Has A Half-Life: Radiopharmaceutical Logistics
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
GxP Inventory Delivers Real-Time Visibility, Operational Efficiency
Modernize your clinical supply chain to streamline global trial operations, ensure regulatory compliance, and deliver investigational therapies to patients efficiently and reliably.
-
Demonstrating The Value Of Investigational Drug Services Through Time-Based Metrics
Learn how adopting time-based metrics helps research teams accurately track workload, optimize staffing, and justify trial budgets.
-
Leveraging A Demand-Led Clinical Supply Model For Program-Level Product Pooling
See how a global biopharmaceutical company was able to address inefficiencies and reduce waste within the clinical supply chain for a high-value therapy that faced strong demand but limited supply.
-
IRT: A New Approach To Meeting The Needs Of Early Phase Trials
As early phase clinical trials become more sophisticated, sponsors are now leveraging flexible IRT solutions to replace error-prone manual processes and gain greater control and efficiency.
-
Winning The Race To FPI With Early Randomization And Trial Supply Management
Learn why the ability to get investigational products to sites, and appropriately store them, is not a given – and this oversight can have serious consequences.
-
Advancing Your API To First Human Dose Trials More Efficiently
Learn how end-to-end support for development and manufacturing, clinical trial services, advanced drug delivery, and commercial packaging can accelerate drug development and time to market.
-
Case Management Accelerates Shipment For SCN1A+ Dravet Syndrome Gene Therapy
Consider this streamlined, end-to-end solution that helped safeguard study timelines and ensured that patients with urgent medical needs could receive treatment without delay.
-
When Protocol Amendments Meet RTSM: From Headache To High-Performance
Learn why an RTSM solution should be adaptive and flexible, and should help clinical trial teams uncover the best ways to handle protocol amendments.
-
Clinical Trial Logistics: What Biopharma Needs To Prepare For Next
Fragmented clinical trial logistics are slowing programs and increasing risk. Learn how coordinated planning and digital visibility are becoming competitive advantages in complex, global studies.
-
Industry Trends: Clinical Logistics Outsourcing
Understanding industry trends, market dynamics, and the selection criteria decision-makers apply when choosing a clinical logistics service provider informs and contextualizes outsourcing decisions.
- Root Causes, Part 5: The Structural Changes Clinical Supply Needs
- Root Causes, Part 4: Why Clinical Supply Teams Are Always Firefighting
- Root Causes, Part 3: The Hidden Cost of Clinical Supply Work That Doesn't Move Trials Forward
- Root Causes, Part 2: The Translation Problem Behind Clinical Trial Execution
CATALENT CORNER
| Insights from Catalent's Clinical Supply Experts |
SPONSORED CONTENT
Impact Of Supplier Choice On APAC Clinical Trial Execution
Learn about strategies Asia-Pacific has become an increasingly complex and congested destination for clinical trials as local and global sponsors alike flock to the region to take advantage of its many benefits, including access to large patient pools. Choosing the right clinical packaging and supply chain partner to support these studies is critical and can vary significantly based upon what countries are involved and the types of services required.